Recent advancements in the development of protein arginine methyltransferases (PRMT) 5 (PRMT5) inhibitors (PRMT5is) represent a significant step forward and a potential therapeutic option for pancreatic cancer treatment. The gene discussed is PRMT5; the disease is pancreatic neoplasm.